We have located links that may give you full text access.
Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients with Vasculogenic Erectile Dysfunction: Is it Dose Dependent?
Urology 2020 October 3
OBJECTIVE: To assess if the effect of intracavernosal injection (ICI) of prostaglandin E1 (PGE1) on duration and rigidity of erection is dose dependent in patients with different types of vasculogenic erectile dysfunction (ED)?
METHODS: A hundred patients with ED were assigned into 4 groups (n=25/each); group (A) patients with arteriogenic ED, group (B) patients with veno-occlusive ED, group (C) patients with mixed (arteriogenic and veno-occlusive) ED and group (D) patients who have only psychogenic ED (control). After ICI of PGE1 patients were assessed using penile doppler ultrasonography and erection hardness score together with calculation of erection duration. The starting dose of PGE1 was 5μg which was increased to 10µg and 20µg as a maximal dose when needed.
RESULTS: The mean PSV of patients in groups A, B, C and D were 24.38±3.3, 37.74±8.28, 22.24±3.85 and 47.76±6.27 respectively. In group D, 88% have achieved the best response at dose of 5 µg while 5.3%, 21.7% and 0% have achieved the best response at dose of 5µg in groups A, B and C respectively (p<0.05 for each). The rest of patients have required either 10 or 20µg to achieve the best response. Patients in group C have required the highest dose of PGE1 to achieve the best response (p<0.05).
CONCLUSION: Intracavernosal injection of PGE1 in escalating doses have improved the rigidity and duration of erection in patients with different types of vasculogenic ED. Patients with mixed arteriogenic and veno-occlusive ED have required the highest dose of PGE1 to achieve the best response.
METHODS: A hundred patients with ED were assigned into 4 groups (n=25/each); group (A) patients with arteriogenic ED, group (B) patients with veno-occlusive ED, group (C) patients with mixed (arteriogenic and veno-occlusive) ED and group (D) patients who have only psychogenic ED (control). After ICI of PGE1 patients were assessed using penile doppler ultrasonography and erection hardness score together with calculation of erection duration. The starting dose of PGE1 was 5μg which was increased to 10µg and 20µg as a maximal dose when needed.
RESULTS: The mean PSV of patients in groups A, B, C and D were 24.38±3.3, 37.74±8.28, 22.24±3.85 and 47.76±6.27 respectively. In group D, 88% have achieved the best response at dose of 5 µg while 5.3%, 21.7% and 0% have achieved the best response at dose of 5µg in groups A, B and C respectively (p<0.05 for each). The rest of patients have required either 10 or 20µg to achieve the best response. Patients in group C have required the highest dose of PGE1 to achieve the best response (p<0.05).
CONCLUSION: Intracavernosal injection of PGE1 in escalating doses have improved the rigidity and duration of erection in patients with different types of vasculogenic ED. Patients with mixed arteriogenic and veno-occlusive ED have required the highest dose of PGE1 to achieve the best response.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app